Hub : Traits :

Worry too long after embarrassment

207 significantly associated models · 49 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 209867116 210585575 1 1 2.5e-07 2.0e-07 1.0e+00 100 SYT14
2 3 35439546 36079910 1 1 1.8e-10 7.0e-13 3.6e-04 75 ARPP21
3 3 135273949 137261517 5 1 1.2e-09 9.6e-10 1.0e+00 100 PCCB
4 5 106500969 108412472 1 1 1.8e-08 6.7e-08 7.8e-02 89 FBXL17
5 5 138933151 140378983 1 1 2.3e-07 7.7e-08 1.2e-01 92 PFDN1
6 8 8092025 11891593 18 1 5.4e-13 3.8e-13 1.9e-02 90 XKR6
7 9 127218258 128824378 3 1 8.3e-10 3.7e-09 1.0e-01 92 PRPS1P2
8 11 12611333 14105497 1 1 5.7e-18 1.8e-21 4.8e-05 82 ARNTL
9 11 56716782 58178587 4 1 1.8e-10 7.8e-11 2.7e-02 88 ZDHHC5
10 11 112486568 113952419 3 2 1.5e-10 4.0e-11 3.7e-01 98 DRD2 TTC12
11 13 110849169 112251122 1 1 2.0e-07 7.1e-07 2.4e-01 94 ANKRD10-IT1
12 16 89375239 90172696 4 1 1.2e-09 4.1e-07 9.5e-01 100 DBNDD1
13 17 1584324 3000009 3 1 2.1e-08 2.2e-07 9.5e-01 100 MNT
14 19 13505333 14978284 2 1 1.3e-07 1.3e-07 1.0e+00 100 PRKACA

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder or Schizophrenia 1.99 2 0 0.0 0.00 1.0e+00 DRD2 PCCB
Depressed Affect (Nagel 2018) 7.09 7 3 6.7 0.94 1.6e-03 ARNTL ARPP21 DRD2 FBXL17 PCCB TTC12 ZDHHC5
Depression (Nagel 2018) 5.23 4 2 4.4 0.99 6.0e-03 DRD2 PCCB TTC12 ZDHHC5
Intelligence (Savage-Jansen 2018) 2.43 3 1 2.2 0.00 1.0e+00 PCCB PFDN1 ZDHHC5
Neuroticism (Nagel 2018) 12.91 11 7 15.6 0.99 2.2e-08 ANKRD10-IT1 ARNTL ARPP21 DRD2 FBXL17 MNT PCCB PRPS1P2 SYT14 TTC12 ZDHHC5
Schizophrenia (2018) 2.72 3 1 2.2 0.00 1.0e+00 DRD2 PCCB ZDHHC5
Schizophrenia vs Biploar Disorder 3.37 1 0 0.0 0.00 1.0e+00 ARNTL
Worry (Nagel 2018) 7.91 9 4 8.9 0.97 8.9e-06 ARNTL ARPP21 DRD2 FBXL17 PCCB PRPS1P2 SYT14 TTC12 ZDHHC5
Major Depression (MDD) 3.62 1 0 0.0 0.00 1.0e+00 ZDHHC5
Reaction Time 2.58 1 1 2.2 0.00 1.0e+00 PFDN1
Verbal and Numeric Reasoning (VNR) 2.38 2 1 2.2 0.00 1.0e+00 PFDN1 ZDHHC5
Lupus 1.74 1 0 0.0 0.00 1.0e+00 XKR6
Neuroticism (2016) 9.31 6 1 2.2 0.97 1.7e-03 ARNTL DRD2 MNT PCCB TTC12 XKR6
Schizophrenia (2014) 3.04 3 1 2.2 0.00 1.0e+00 DRD2 PCCB ZDHHC5
Blood Eosinophil Count 0.48 1 0 0.0 0.00 1.0e+00 FBXL17
Blood Platelet Count 1.07 3 3 6.7 0.00 1.0e+00 MNT PCCB ZDHHC5
Blood Red Count 1.06 6 2 4.4 -0.19 7.2e-01 ANKRD10-IT1 ARNTL DRD2 MNT SYT14 ZDHHC5
Blood White Count 0.77 3 0 0.0 0.00 1.0e+00 PCCB PRPS1P2 TTC12
Heel T-Score 0.92 4 0 0.0 0.06 9.4e-01 DBNDD1 MNT SYT14 ZDHHC5
BMI 2.68 5 4 8.9 -0.59 2.9e-01 ARNTL ARPP21 PFDN1 SYT14 TTC12
Height 0.81 3 2 4.4 0.00 1.0e+00 DBNDD1 PCCB PRKACA
Waist Hip Ratio (WHR) 1.62 3 1 2.2 0.00 1.0e+00 PCCB PRPS1P2 TTC12
Systolic Blood Pressure 1.98 3 3 6.7 0.00 1.0e+00 ARNTL PRPS1P2 ZDHHC5
Smoking Status 2.67 2 1 2.2 0.00 1.0e+00 PRPS1P2 SYT14
Cardiovascular Disease 1.93 4 0 0.0 -0.53 4.7e-01 ARNTL DRD2 PCCB TTC12
Lung FEV1/FVC ratio 0.66 1 0 0.0 0.00 1.0e+00 ZDHHC5
Lung FVC 1.17 1 1 2.2 0.00 1.0e+00 SYT14
Neuroticism 12.77 10 7 15.6 0.98 9.5e-07 ARNTL ARPP21 DRD2 FBXL17 MNT PCCB PFDN1 PRPS1P2 TTC12 ZDHHC5
Hair Pigment 96.40 1 1 2.2 0.00 1.0e+00 DBNDD1
Tanning 88.36 2 1 2.2 0.00 1.0e+00 DBNDD1 PFDN1
Hand grip strength (left) 2.06 2 0 0.0 0.00 1.0e+00 ARPP21 PRKACA
Number of treatments/medications taken 1.68 1 0 0.0 0.00 1.0e+00 TTC12
Sensitivity / hurt feelings 7.93 6 3 6.7 0.99 2.4e-04 DRD2 PCCB PRPS1P2 TTC12 XKR6 ZDHHC5
Frequency of depressed mood in last 2 weeks 4.88 3 0 0.0 0.00 1.0e+00 DRD2 PCCB ZDHHC5
Hearing difficulty/problems: Yes 3.10 1 0 0.0 0.00 1.0e+00 FBXL17
Relative age of first facial hair 3.13 1 1 2.2 0.00 1.0e+00 DBNDD1
Other serious medical condition/disability diagnosed by doctor 2.96 2 0 0.0 0.00 1.0e+00 ANKRD10-IT1 TTC12
Systolic blood pressure, automated reading 2.82 4 1 2.2 -0.98 1.8e-02 ARNTL PRPS1P2 XKR6 ZDHHC5
Pack years adult smoking proportion 2.96 1 0 0.0 0.00 1.0e+00 MNT
Impedance of leg (right) 3.17 5 3 6.7 0.68 2.1e-01 DBNDD1 MNT PFDN1 PRPS1P2 XKR6
Leg fat-free mass (left) 1.64 3 2 4.4 0.00 1.0e+00 PRPS1P2 SYT14 XKR6
Trunk fat percentage 2.87 6 0 0.0 -0.10 8.6e-01 ARNTL ARPP21 MNT SYT14 TTC12 ZDHHC5
Hand grip strength (right) 1.64 1 0 0.0 0.00 1.0e+00 ARPP21
Current tobacco smoking 3.19 2 0 0.0 0.00 1.0e+00 PRPS1P2 XKR6
Fed-up feelings 7.01 7 3 6.7 0.99 4.6e-05 ANKRD10-IT1 ARNTL DRD2 PCCB TTC12 XKR6 ZDHHC5
Frequency of unenthusiasm / disinterest in last 2 weeks 5.20 4 0 0.0 1.00 5.6e-04 DRD2 PCCB TTC12 ZDHHC5
Relative age voice broke 2.25 2 0 0.0 0.00 1.0e+00 DBNDD1 PCCB
Age when periods started (menarche) 1.62 1 1 2.2 0.00 1.0e+00 ARNTL
Heel bone mineral density (BMD) T-score, automated (left) 3.15 1 1 2.2 0.00 1.0e+00 XKR6
High blood pressure 3.07 3 1 2.2 0.00 1.0e+00 ARNTL DBNDD1 XKR6
Stomach or abdominal pain in last month 1.75 1 0 0.0 0.00 1.0e+00 PCCB
Medication: Levothyroxine sodium 1.06 1 0 0.0 0.00 1.0e+00 XKR6
Sitting height 1.04 4 1 2.2 -1.00 2.4e-03 DBNDD1 PRKACA PRPS1P2 ZDHHC5
Body mass index (BMI) 3.43 5 4 8.9 -0.86 5.8e-02 ARNTL ARPP21 PFDN1 SYT14 XKR6
Impedance of leg (left) 3.17 5 3 6.7 0.70 1.9e-01 DBNDD1 MNT PFDN1 PRPS1P2 XKR6
Leg predicted mass (left) 1.66 3 2 4.4 0.00 1.0e+00 PRPS1P2 SYT14 XKR6
Trunk fat mass 2.67 6 1 2.2 -0.56 2.5e-01 ARNTL ARPP21 SYT14 TTC12 XKR6 ZDHHC5
Waist circumference 2.75 4 2 4.4 -0.60 4.0e-01 ARNTL ARPP21 SYT14 TTC12
Past tobacco smoking 2.91 2 0 0.0 0.00 1.0e+00 ANKRD10-IT1 PRPS1P2
Alcohol usually taken with meals 5.29 2 1 2.2 0.00 1.0e+00 MNT ZDHHC5
Nervous feelings 9.17 6 2 4.4 0.97 1.7e-03 ANKRD10-IT1 ARNTL PCCB PRPS1P2 TTC12 XKR6
Frequency of tenseness / restlessness in last 2 weeks 5.44 3 1 2.2 0.00 1.0e+00 DRD2 PCCB TTC12
Hearing difficulty/problems with background noise 2.46 1 0 0.0 0.00 1.0e+00 TTC12
Forced vital capacity (FVC) 1.29 2 0 0.0 0.00 1.0e+00 DBNDD1 SYT14
Heel bone mineral density (BMD) T-score, automated (right) 3.09 2 1 2.2 0.00 1.0e+00 DBNDD1 XKR6
Qualifications: None of the above 1.70 1 0 0.0 0.00 1.0e+00 ZDHHC5
Financial difficulties in last 2 years 2.89 1 0 0.0 0.00 1.0e+00 DRD2
Fluid intelligence score 2.00 2 0 0.0 0.00 1.0e+00 PCCB PFDN1
Neuroticism score 15.42 11 8 17.8 0.97 4.0e-07 ANKRD10-IT1 ARNTL ARPP21 DRD2 FBXL17 MNT PCCB PRPS1P2 TTC12 XKR6 ZDHHC5
Weight 2.11 5 2 4.4 -0.78 1.2e-01 ARNTL ARPP21 SYT14 TTC12 XKR6
Impedance of arm (right) 2.50 5 1 2.2 0.68 2.1e-01 DBNDD1 PFDN1 PRPS1P2 XKR6 ZDHHC5
Arm fat percentage (right) 3.52 7 4 8.9 -0.32 4.9e-01 ARNTL ARPP21 PRKACA SYT14 TTC12 XKR6 ZDHHC5
Trunk fat-free mass 1.24 2 1 2.2 0.00 1.0e+00 PRPS1P2 XKR6
Hip circumference 2.20 3 1 2.2 0.00 1.0e+00 SYT14 TTC12 XKR6
Father's age at death 1.37 1 0 0.0 0.00 1.0e+00 XKR6
Worrier / anxious feelings 10.43 8 3 6.7 0.96 1.1e-04 ARNTL ARPP21 DRD2 FBXL17 PCCB PRPS1P2 XKR6 ZDHHC5
Frequency of tiredness / lethargy in last 2 weeks 5.06 4 1 2.2 1.00 2.8e-03 DRD2 MNT TTC12 ZDHHC5
Number of live births 1.31 1 0 0.0 0.00 1.0e+00 DBNDD1
Forced expiratory volume in 1-second (FEV1) 1.34 1 0 0.0 0.00 1.0e+00 PRPS1P2
Serious illness, injury or assault of a close relative in last 2 years 2.28 1 0 0.0 0.00 1.0e+00 XKR6
Impedance of arm (left) 2.19 5 1 2.2 0.63 2.5e-01 DBNDD1 PFDN1 PRPS1P2 XKR6 ZDHHC5
Arm fat mass (right) 3.28 6 4 8.9 -0.67 1.5e-01 ARNTL ARPP21 SYT14 TTC12 XKR6 ZDHHC5
Trunk predicted mass 1.26 2 1 2.2 0.00 1.0e+00 PRPS1P2 XKR6
Standing height 1.03 2 1 2.2 0.00 1.0e+00 DBNDD1 PRKACA
Tense / 'highly strung' 7.79 5 1 2.2 1.00 1.5e-04 DRD2 FBXL17 PCCB TTC12 XKR6
Seen doctor (GP) for nerves, anxiety, tension or depression 4.50 3 1 2.2 0.00 1.0e+00 DRD2 TTC12 ZDHHC5
Hair/balding pattern: Pattern 4 1.60 2 0 0.0 0.00 1.0e+00 DBNDD1 SYT14
Peak expiratory flow (PEF) 2.31 2 0 0.0 0.00 1.0e+00 PRPS1P2 XKR6
Headache pain in last month 2.23 1 0 0.0 0.00 1.0e+00 ZDHHC5
Hypothyroidism/myxoedema (self-reported) 1.65 1 1 2.2 0.00 1.0e+00 XKR6
Body fat percentage 3.15 6 1 2.2 -0.10 8.4e-01 ARNTL ARPP21 MNT SYT14 TTC12 ZDHHC5
Leg fat percentage (right) 3.11 6 1 2.2 -0.38 4.5e-01 ARNTL ARPP21 MNT SYT14 TTC12 XKR6
Arm fat-free mass (right) 1.45 2 2 4.4 0.00 1.0e+00 PRPS1P2 XKR6
Comparative body size at age 10 2.50 2 1 2.2 0.00 1.0e+00 PRKACA XKR6
Number of full brothers 2.27 1 0 0.0 0.00 1.0e+00 ARPP21
Wheeze or whistling in the chest in last year 1.86 1 0 0.0 0.00 1.0e+00 TTC12
Health satisfaction 2.79 1 0 0.0 0.00 1.0e+00 DRD2
Qualifications: College or University degree 1.99 3 1 2.2 0.00 1.0e+00 MNT PFDN1 ZDHHC5
Medication: Blood pressure 1.62 1 0 0.0 0.00 1.0e+00 XKR6
Mean time to correctly identify matches 2.96 1 1 2.2 0.00 1.0e+00 PFDN1
Whole body fat mass 2.90 5 1 2.2 -0.70 1.9e-01 ARNTL ARPP21 SYT14 TTC12 XKR6
Leg fat mass (right) 3.19 5 3 6.7 -0.73 1.6e-01 ARNTL ARPP21 SYT14 TTC12 XKR6
Arm predicted mass (right) 1.50 2 2 4.4 0.00 1.0e+00 PRPS1P2 XKR6
Pulse rate, automated reading 1.51 1 0 0.0 0.00 1.0e+00 ZDHHC5
Alcohol intake frequency. 2.69 4 0 0.0 -0.58 4.2e-01 DRD2 SYT14 TTC12 ZDHHC5
Comparative height size at age 10 0.68 2 0 0.0 0.00 1.0e+00 PCCB TTC12
Suffer from 'nerves' 5.77 4 1 2.2 1.00 2.7e-03 DRD2 FBXL17 TTC12 XKR6
Overall health rating 3.57 4 1 2.2 0.58 4.2e-01 DRD2 MNT TTC12 XKR6
Hypertension (Self-reported) 3.11 3 1 2.2 0.00 1.0e+00 ARNTL DBNDD1 XKR6
Whole body fat-free mass 1.37 2 2 4.4 0.00 1.0e+00 PRPS1P2 XKR6
Leg fat-free mass (right) 1.60 3 2 4.4 0.00 1.0e+00 PRPS1P2 SYT14 XKR6
Arm fat percentage (left) 3.51 6 4 8.9 -0.61 2.0e-01 ARNTL ARPP21 SYT14 TTC12 XKR6 ZDHHC5
Average weekly red wine intake 3.34 2 0 0.0 0.00 1.0e+00 MNT ZDHHC5
Mood swings 6.18 4 3 6.7 0.98 1.6e-02 DRD2 TTC12 XKR6 ZDHHC5
Loneliness, isolation 3.74 1 0 0.0 0.00 1.0e+00 ARNTL
Long-standing illness, disability or infirmity 1.82 1 0 0.0 0.00 1.0e+00 TTC12
Medication for cholesterol 1.66 1 0 0.0 0.00 1.0e+00 XKR6
Smoking status: Current 3.26 2 0 0.0 0.00 1.0e+00 PRPS1P2 XKR6
Whole body water mass 1.37 2 2 4.4 0.00 1.0e+00 PRPS1P2 XKR6
Leg predicted mass (right) 1.59 3 2 4.4 0.00 1.0e+00 PRPS1P2 SYT14 XKR6
Arm fat mass (left) 3.24 5 4 8.9 -0.77 1.3e-01 ARNTL ARPP21 SYT14 TTC12 XKR6
Number of self-reported non-cancer illnesses 2.12 2 0 0.0 0.00 1.0e+00 ARNTL TTC12
Miserableness 7.45 6 3 6.7 0.96 3.0e-03 ARNTL ARPP21 DRD2 PCCB TTC12 XKR6
Guilty feelings 10.61 7 3 6.7 0.97 2.1e-04 ARNTL ARPP21 DRD2 PFDN1 TTC12 XKR6 ZDHHC5
Medication: Blood pressure 2.83 1 1 2.2 0.00 1.0e+00 XKR6
Medication: Bendroflumethiazide 2.93 1 1 2.2 0.00 1.0e+00 XKR6
Ever smoked 2.76 1 0 0.0 0.00 1.0e+00 PRPS1P2
Basal metabolic rate 1.51 3 2 4.4 0.00 1.0e+00 PRPS1P2 SYT14 XKR6
Leg fat percentage (left) 3.21 6 1 2.2 -0.40 4.3e-01 ARNTL ARPP21 MNT SYT14 TTC12 XKR6
Arm fat-free mass (left) 1.39 2 1 2.2 0.00 1.0e+00 PRPS1P2 XKR6
Average weekly beer plus cider intake 2.39 1 0 0.0 0.00 1.0e+00 XKR6
Irritability 7.52 5 1 2.2 0.99 1.1e-03 ANKRD10-IT1 ARPP21 DRD2 FBXL17 XKR6
Risk taking 2.93 2 0 0.0 0.00 1.0e+00 PCCB XKR6
Diastolic blood pressure, automated reading 2.34 2 2 4.4 0.00 1.0e+00 ARNTL XKR6
Unable to work because of sickness or disability 3.28 2 0 0.0 0.00 1.0e+00 ARPP21 ZDHHC5
Commuting to job workplace: Cycle 2.01 1 0 0.0 0.00 1.0e+00 MNT
Vascular/heart problems diagnosed by doctor 2.75 3 1 2.2 0.00 1.0e+00 ARNTL DBNDD1 XKR6
Basal cell carcinoma (self-reported) 4.49 1 1 2.2 0.00 1.0e+00 DBNDD1
Pack years of smoking 2.82 1 0 0.0 0.00 1.0e+00 MNT
Impedance of whole body 2.87 5 3 6.7 0.49 4.0e-01 DBNDD1 MNT PFDN1 PRPS1P2 XKR6
Leg fat mass (left) 3.17 5 3 6.7 -0.73 1.6e-01 ARNTL ARPP21 SYT14 TTC12 XKR6
Arm predicted mass (left) 1.47 2 2 4.4 0.00 1.0e+00 PRPS1P2 XKR6

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 2 0.057 1.7
GTEx Adipose Visceral Omentum 3 0.147 1.7
GTEx Adrenal Gland 2 0.137 1.8
GTEx Artery Aorta 4 0.134 1.8
GTEx Artery Coronary 2 0.169 1.8
GTEx Artery Tibial 4 0.106 1.7
GTEx Brain Caudate basal ganglia 1 0.109 1.8
GTEx Brain Cerebellar Hemisphere 2 0.134 1.8
GTEx Brain Cerebellum 3 0.151 1.7
GTEx Brain Cortex 1 0.097 1.9
GTEx Brain Frontal Cortex BA9 1 0.108 1.8
GTEx Brain Hippocampus 0 0.000 1.7
GTEx Brain Hypothalamus 0 0.000 1.8
GTEx Brain Nucleus accumbens basal ganglia 0 0.000 1.8
GTEx Brain Putamen basal ganglia 1 0.160 1.8
GTEx Breast Mammary Tissue 4 0.203 1.8
GTEx Breast Mammary Tissue (Male) 2 0.168 1.7
GTEx Breast Mammary Tissue (Female) 2 0.122 1.7
GTEx Cells EBV-transformed lymphocytes 2 0.141 1.8
GTEx Cells Transformed fibroblasts 3 0.071 1.7
GTEx Colon Sigmoid 4 0.274 1.8
GTEx Colon Transverse 5 0.242 1.8
GTEx Esophagus Gastroesophageal Junction 2 0.138 1.9
GTEx Esophagus Mucosa 7 0.211 1.7
GTEx Esophagus Muscularis 4 0.124 1.8
GTEx Heart Atrial Appendage 3 0.190 1.8
GTEx Heart Left Ventricle 4 0.261 1.8
GTEx Liver 0 0.000 1.6
GTEx Lung 6 0.209 1.7
GTEx Muscle Skeletal 4 0.138 1.7
GTEx Nerve Tibial 4 0.093 1.7
GTEx Ovary 0 0.000 1.9
GTEx Pancreas 5 0.306 1.8
GTEx Pituitary 1 0.090 1.7
GTEx Prostate 1 0.120 1.8
GTEx Skin Not Sun Exposed Suprapubic 5 0.203 1.8
GTEx Skin Sun Exposed Lower leg 6 0.165 1.7
GTEx Small Intestine Terminal Ileum 2 0.434 1.9
GTEx Spleen 3 0.213 1.8
GTEx Stomach 3 0.206 1.8
GTEx Testis 4 0.127 1.7
GTEx Thyroid 3 0.075 1.7
GTEx Uterus 2 0.353 1.9
GTEx Vagina 2 0.315 2.0
GTEx Whole Blood 1 0.050 1.7
METSIM Adipose 1 0.022 1.6
NTR Blood 2 0.083 1.6
ROSMAP Brain Pre-frontal Cortex 11 0.251 1.8
YFS Blood 2 0.043 1.5
CommonMind Brain Pre-frontal Cortex 3 0.056 1.6
The Cancer Genome Atlas Bladder Urothelial Carcinoma 2 0.121 1.6
The Cancer Genome Atlas Breast Invasive Carcinoma 3 0.068 1.6
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 0 0.000 1.6
The Cancer Genome Atlas Colon Adenocarcinoma 4 0.194 1.6
The Cancer Genome Atlas Esophageal Carcinoma 3 0.438 1.9
The Cancer Genome Atlas Glioblastoma Multiforme 1 0.098 1.6
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 5 0.184 1.6
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 5 0.122 1.6
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 4 0.195 1.6
The Cancer Genome Atlas Brain Lower Grade Glioma 4 0.093 1.6
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 2 0.181 1.7
The Cancer Genome Atlas Lung Adenocarcinoma 6 0.204 1.6
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 5 0.200 1.7
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 3 0.188 1.6
The Cancer Genome Atlas Pancreatic Adenocarcinoma 1 0.060 1.7
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 2 0.151 1.6
The Cancer Genome Atlas Prostate Adenocarcinoma 6 0.130 1.6
The Cancer Genome Atlas Rectum Adenocarcinoma 0 0.000 1.6
The Cancer Genome Atlas Soft Tissue Sarcoma 2 0.187 1.6
The Cancer Genome Atlas Skin Cutaneous Melanoma 0 0.000 1.5
The Cancer Genome Atlas Stomach Adenocarcinoma 4 0.238 1.6
The Cancer Genome Atlas Testicular Germ Cell Tumors 2 0.156 1.6
The Cancer Genome Atlas Thyroid Carcinoma 4 0.078 1.6
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 0 0.000 1.5